Kodiak Sciences Inc. (KOD) - Stock Analysis
Last updated: Apr 22, 2026
HealthcareClosed
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
KOD has one of the clearest biotech catalysts: positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy drove a major rerating, headlines cited possible faster BLA timing, and the stock rallied about 110% over 21 trading days, making it a strong event-driven near-term candidate despite volatility.
Loading chart data...
Idea window: 4/22/2026 – 4/29/2026Sector: Healthcare
AI Analyst Overview
Loading AI Analyst data...
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 22 | Apr 29 | KOD | Kodiak Sciences Inc. | KOD has one of the clearest biotech catalysts: positive Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy drove a major rerating, headlines cited possible faster BLA timing, and the stock rallied about 110% over 21 trading days, making it a strong event-driven near-term candidate despite volatility. | Closed | -3.4% |
| Mar 30 | Apr 6 | KOD | Kodiak Sciences Inc. | KOD is a high‑risk, high‑reward clinical‑data momentum trade: late‑March Phase 3 Zenkuda data showed clear superiority versus sham and triggered a >20% 21‑day surge and 52‑week high, with strong follow‑through buying despite weak fundamentals, offering further upside potential while clinical and regulatory headlines stay favorable. | Closed | +15.9% |